40 Participants Needed

Oxytocin for Postpartum Hemorrhage

Mrinalini Balki, MD profile photo
Overseen ByMrinalini Balki, MD
Age: 18 - 65
Sex: Female
Trial Phase: Academic
Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Must be taking: Oxytocin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug oxytocin for postpartum hemorrhage?

Oxytocin is widely used as the standard treatment to prevent postpartum hemorrhage, which is a leading cause of maternal death. It is routinely administered after childbirth to help the uterus contract and reduce bleeding.12345

Is oxytocin safe for use in humans?

Oxytocin, including its synthetic form Syntocinon, has been used safely in thousands of patients without observed side effects like vasospasm (narrowing of blood vessels) or anaphylactic reaction (severe allergic reaction). It is generally considered safe when used with proper supervision and dosage adjustment.23678

How is the drug oxytocin unique in treating postpartum hemorrhage?

Oxytocin is unique because it is the most commonly used drug to prevent postpartum hemorrhage, and it can be administered both intravenously (through a vein) and intramuscularly (into a muscle), making it versatile for different settings, including emergencies and low-resource areas.59101112

What is the purpose of this trial?

This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient.The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.

Research Team

Mrinalini Balki | Department of Physiology

Mrinalini Balki, MD

Principal Investigator

MOUNT SINAI HOSPITAL

Eligibility Criteria

This trial is for women in labor who are having a cesarean delivery under neuraxial anesthesia and have been exposed to oxytocin for at least 3 hours. It's not suitable for those with hypertension, severe heart issues, allergies to oxytocin, contraindications to neuraxial anesthesia, or if general anesthesia becomes necessary during surgery.

Inclusion Criteria

I had labor induced or augmented and will have a cesarean with spinal or epidural anesthesia after at least 3 hours of oxytocin.

Exclusion Criteria

I refuse to sign the consent form for this trial.
All patients who declare allergy or hypersensitivity to oxytocin
I have a history of high blood pressure or serious heart conditions.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive varying doses of oxytocin infusion to determine the minimal effective dose for maintaining uterine tone during cesarean delivery

2 hours
Intraoperative monitoring

Postoperative Monitoring

Participants are monitored for uterine tone and other physiological responses in the post anesthetic care unit (PACU)

2 hours
Continuous monitoring in PACU

Follow-up

Participants are monitored for safety and effectiveness after treatment, including blood loss and need for additional uterotonic medication

24 hours

Treatment Details

Interventions

  • Oxytocin
Trial Overview The study aims to find the lowest effective dose of oxytocin infusion needed after an initial bolus dose during cesarean delivery. The dosage will be adjusted up or down based on the previous patient's uterine response, aiming for better control of blood loss post-delivery.
Participant Groups
10Treatment groups
Experimental Treatment
Group I: Oxytocin infusion rate 6 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 6 IU/h.
Group II: Oxytocin infusion rate 4 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 4 IU/h.
Group III: Oxytocin infusion rate 36 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 36 IU/h.
Group IV: Oxytocin infusion rate 34 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 34 IU/h.
Group V: Oxytocin infusion rate 30 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 30 IU/h.
Group VI: Oxytocin infusion rate 26 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 26 IU/h.
Group VII: Oxytocin infusion rate 22 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 22 IU/h.
Group VIII: Oxytocin infusion rate 18 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 18 IU/h.
Group IX: Oxytocin infusion rate 14 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 14 IU/h.
Group X: Oxytocin infusion rate 10 IU/hExperimental Treatment1 Intervention
The maintenance infusion rate of oxytocin will be 10 IU/h.

Oxytocin is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Pitocin for:
  • Induction of labor
  • Augmentation of labor
  • Control of postpartum bleeding
🇪🇺
Approved in European Union as Syntocinon for:
  • Induction of labor
  • Augmentation of labor
  • Control of postpartum bleeding
🇨🇦
Approved in Canada as Oxytocin for:
  • Induction of labor
  • Augmentation of labor
  • Control of postpartum bleeding

Find a Clinic Near You

Who Is Running the Clinical Trial?

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Lead Sponsor

Trials
132
Recruited
11,400+

Findings from Research

In a study of 34 women undergoing elective cesarean sections, carbetocin was administered either as a bolus or an infusion, and both methods showed no significant differences in hemodynamic effects, indicating that the administration method does not impact its safety profile.
Carbetocin, a newer uterotonic agent, offers a longer duration of action compared to oxytocin, making it a potentially more effective option for preventing postpartum hemorrhage without the need for additional doses after delivery.
Hemodynamic effects of carbetocin administered as an intravenous bolus or infusion during cesarean delivery.Kwon, K., Kim, D., Jo, H., et al.[2022]
In a study of 160 hypertensive pregnant women undergoing cesarean section, carbetocin was found to significantly reduce postoperative blood loss compared to oxytocin, with blood loss averaging 424.75 ml in the carbetocin group versus 679.5 ml in the oxytocin group.
Carbetocin also maintained hemoglobin levels post-delivery, while oxytocin led to a significant decrease in hemoglobin, indicating that carbetocin may be a safer option for preventing postpartum hemorrhage in this patient population.
Carbetocin versus oxytocin for prevention of postpartum hemorrhage in hypertensive women undergoing elective cesarean section.Ibrahim, ZM., Sayed Ahmed, WA., Abd El-Hamid, EM., et al.[2021]
In a systematic review of 24 studies involving 37,383 patients, carbetocin was found to be more effective than oxytocin in reducing postpartum hemorrhage (PPH) and the need for additional uterine contractions in both cesarean and vaginal deliveries.
Carbetocin also showed a lower incidence of headaches compared to oxytocin in cesarean section patients, while both drugs had similar safety profiles regarding other side effects, suggesting that carbetocin is a promising alternative for preventing PPH.
Effectiveness and safety of carboxytocin versus oxytocin in preventing postpartum hemorrhage: A systematic review and meta-analysis.Sun, H., Xu, L., Li, Y., et al.[2022]

References

Hemodynamic effects of carbetocin administered as an intravenous bolus or infusion during cesarean delivery. [2022]
Carbetocin versus oxytocin for prevention of postpartum hemorrhage in hypertensive women undergoing elective cesarean section. [2021]
Effectiveness and safety of carboxytocin versus oxytocin in preventing postpartum hemorrhage: A systematic review and meta-analysis. [2022]
Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. [2022]
[The Role of Oxytocin in the Prevention of Postpartum Hemorrhage in Low-Resource Settings]. [2022]
Synthetic oxytocin. [2018]
A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour. [2021]
Carbetocin for the prevention of postpartum hemorrhage: a systematic review. [2018]
A survey of physicians' attitudes toward uterotonic administration in parturients undergoing cesarean section. [2019]
The risk of postpartum hemorrhage when lowering the oxytocin dose in planned cesarean section, a pilot study. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Role of oxytocin in prevention of postpartum hemorrhage in unplanned out-of-hospital deliveries treated by emergency medical services. [2020]
12.United Statespubmed.ncbi.nlm.nih.gov
Dose and duration of oxytocin to prevent postpartum hemorrhage: a review. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security